NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis $311.77 -5.39 (-1.70%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$316.34 +4.57 (+1.47%) As of 06/6/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Insulet Stock (NASDAQ:PODD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Insulet alerts:Sign Up Key Stats Today's Range$311.06▼$320.9850-Day Range$238.57▼$327.4752-Week Range$173.00▼$329.33Volume682,612 shsAverage Volume708,505 shsMarket Capitalization$21.94 billionP/E Ratio53.85Dividend YieldN/APrice Target$318.41Consensus RatingModerate Buy Company OverviewInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More… Insulet Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScorePODD MarketRank™: Insulet scored higher than 83% of companies evaluated by MarketBeat, and ranked 154th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth26.79% Earnings GrowthEarnings for Insulet are expected to grow by 26.79% in the coming year, from $3.92 to $4.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 53.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 53.85, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.23.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.62. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 29.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.27% of the float of Insulet has been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 2.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-1.20 Percentage of Shares Shorted3.27% of the float of Insulet has been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 2.70%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.87 News SentimentInsulet has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Insulet this week, compared to 13 articles on an average week.Search Interest15 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows7 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,182,760.00 in company stock.Percentage Held by InsidersOnly 0.39% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Stock News HeadlinesInsulet Co. (NASDAQ:PODD) SVP John W. Kapples Sells 5,278 SharesMay 16, 2025 | insidertrades.comInsulet Surges on Q1 Beat, Emerges as a Top S&P 500 PerformerInsulet's earnings and upgraded guidance recently propelled its stock to S&P 500 leadership, showcasing strong execution in the diabetes care market.May 14, 2025 | marketbeat.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.June 7, 2025 | Timothy Sykes (Ad)Asian shares advance as details awaited on progress in China-US trade talksAsian shares are higher after two days of trade talks between China and the U_S_ made what the U_S_ side said was “substantial progress.”May 12, 2025 | marketbeat.comQ1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top MarksJune 6 at 5:23 AM | msn.comTD Cowen Raises Insulet (PODD) Price Target, Maintains Buy RatingJune 5 at 1:17 PM | insidermonkey.comReflecting On Patient Monitoring Stocks’ Q1 Earnings: Masimo (NASDAQ:MASI)June 3, 2025 | msn.com1 Surging Stock with Exciting Potential and 2 to QuestionJune 2, 2025 | finance.yahoo.comSee More Headlines PODD Stock Analysis - Frequently Asked Questions How have PODD shares performed this year? Insulet's stock was trading at $261.07 on January 1st, 2025. Since then, PODD stock has increased by 19.4% and is now trading at $311.77. View the best growth stocks for 2025 here. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) issued its quarterly earnings data on Thursday, May, 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. Read the conference call transcript. Who are Insulet's major shareholders? Insulet's top institutional shareholders include Vanguard Group Inc. (12.32%), Baillie Gifford & Co. (3.20%), American Century Companies Inc. (1.64%) and Groupama Asset Managment (1.50%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, John W Kapples, Wayde D Mcmillan, Bret Christensen, Mark N Field, Eric Benjamin, Michael P Spears, Lauren Budden, Dan Manea, Prem Singh, Wayne AI Frederick, Shacey Petrovic and Luciana Borio. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC). Company Calendar Last Earnings5/08/2025Today6/07/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees2,600Year Founded2000Price Target and Rating Average Stock Price Target$318.41 High Stock Price Target$380.00 Low Stock Price Target$223.00 Potential Upside/Downside+2.1%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$5.56 Trailing P/E Ratio53.85 Forward P/E Ratio79.53 P/E Growth3.62Net Income$206.30 million Net Margins20.19% Pretax Margin14.95% Return on Equity24.46% Return on Assets8.33% Debt Debt-to-Equity Ratio1.21 Current Ratio3.68 Quick Ratio2.80 Sales & Book Value Annual Sales$2.20 billion Price / Sales9.98 Cash Flow$4.10 per share Price / Cash Flow75.96 Book Value$10.49 per share Price / Book29.72Miscellaneous Outstanding Shares70,375,000Free Float69,815,000Market Cap$21.94 billion OptionableOptionable Beta1.37 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:PODD) was last updated on 6/7/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.